The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Open Positions

Current vacancies in Lund Stem Cell Center Research Groups:


21 Doctoral Fellowship Positions available via the RAMP-UP Doctoral Programme

The RAMP-UP Doctoral Programme is now accepting applications for up to 21 fully funded PhD positions in regenerative medicine and advanced therapy medicinal products (ATMPs).

RAMP-UP is a Horizon Europe Marie Skłodowska-Curie COFUND doctoral programme coordinated by Lund Stem Cell Center, offering interdisciplinary research training, international mobility, and full employment at one of four leading European universities:

  • Lund University (Sweden)
  • Leiden University Medical Center (Netherlands)
  • Hannover Medical School (Germany)
  • DTU - Technical University of Denmark (Denmark)

If you are an early-career researcher ready to work at the forefront of advanced therapies, we invite you to apply. We strongly encourage applications from individuals from underrepresented backgrounds.

Application Deadline: 30 March, 2026


Doctoral Candidate Position - part of the ACHILLES MSCA Doctoral Network

Associate Prof. Marcus Järås, head of the Targeted Therapies in Leukemia research group at Lund Stem Cell Center, is currently recruiting an industrial Doctoral Candidate for a project that has been selected to be part of the ACHILLES Marie Skłodowska Curie Action (MSCA) Doctoral Network (DN) funded by the European Commission under Horizon Europe program. 

The project titled 'Development of Therapeutic Antibodies for Treating Acute Myeloid Leukemia (AML),'  will be conducted together with  Lead Biologicals International AB, located in Lund. The primary objective of this project is to develop therapeutic antibodies for the treatment of AML. The specific objectives of this project are:

  1. Generating high-affinity antibodies that are specific to AML and capable of restoring immune surveillance against leukemia cells by performing single-cell sequencing of rabbit B-cells using the 10x Genomics platform.
  2. Testing the binding affinity and specificity of the generated antibodies against AML cells.
  3. Translating these results into effective treatment options for AML patients by enhancing immune responses with improved specificity and efficacy.

Application Deadline: 28 February, 2026


For bachelor and master students looking to propose a dissertation topic or for internships, please visit our research groups pages and Bachelor and Master portal. You are more than welcome to contact our Principal Investigators directly.